Genfit SA
NASDAQ:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (3.2), the stock would be worth $4.4 (26% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.3 | $5.97 |
0%
|
| 3-Year Average | 3.2 | $4.4 |
-26%
|
| 5-Year Average | 3.2 | $4.4 |
-26%
|
| Industry Average | 10.7 | $14.74 |
+147%
|
| Country Average | 1.4 | $1.98 |
-67%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$338.8m
|
/ |
Jan 2026
€71.1m
|
= |
|
|
$338.8m
|
/ |
Dec 2026
€70.2m
|
= |
|
|
$338.8m
|
/ |
Dec 2027
€103.2m
|
= |
|
|
$338.8m
|
/ |
Dec 2028
€67m
|
= |
|
|
$338.8m
|
/ |
Dec 2029
€70.6m
|
= |
|
|
$338.8m
|
/ |
Dec 2030
€118.3m
|
= |
|
|
$338.8m
|
/ |
Dec 2031
€183.7m
|
= |
|
|
$338.8m
|
/ |
Dec 2032
€242.3m
|
= |
|
|
$338.8m
|
/ |
Dec 2033
€322.4m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
G
|
Genfit SA
NASDAQ:GNFT
|
404.8m USD | 4.3 | -4.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 6.6 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 6.1 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 5.8 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 8.4 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 3.9 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 10.3 | 36.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 3.3 | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.8 |
| Median | 1.4 |
| 70th Percentile | 2.8 |
| Max | 29 441 857.7 |
Other Multiples
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
